Moderna director Abbas sells $264,951 in shares
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Moderna Inc (MRNA)
This is the main Moderna stock price chart and current quotes. You can find more details about MRNA stock by going to one of our multiple sections under this page such as historical data, price charts, technical analysis and others.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
45.29
47.97
52 wk Range
22.28
59.55
MRNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
45.2947.97
52 wk Range
22.2859.55
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MRNA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
42.89
Downside
-9.31%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Moderna receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Moderna receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Moderna director Abbas sells $264,951 in shares
- Investing.com
- Moderna receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Moderna receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Moderna receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Moderna receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
Analyst Ratings
4 Buy
16 Hold
3 Sell
Ratings:
23 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 42.89
(-9.31% Downside)
Moderna Inc SWOT Analysis
Market Outlook | Learn about Moderna's competitive positioning, with analyst price targets ranging from $28 to $45, as it navigates regulatory hurdles and intense industry competition |
Pipeline Potential | Discover Moderna's promising oncology pipeline and upcoming vaccine approvals, with analysts eyeing long-term value in cancer treatments and combination vaccines |
Financial Challenges | Delve into Moderna's financial performance, including revenue decline and cost-cutting measures, as it aims for profitability by 2028 amid evolving market dynamics |
mRNA Pioneer's Pivot | Explore Moderna's strategic shift beyond COVID-19 vaccines, leveraging its innovative mRNA platform to diversify revenue streams and expand into new therapeutic areas |
Moderna Inc Earnings Call Summary for Q1/2026
- Q1 2026 revenue hit $400M, beating forecasts by 54.51%, with 80% from international sales, particularly the UK market.
- EPS loss of $3.40 missed estimates by 68%, largely due to $878M litigation settlement charge impacting cost of sales.
- Stock rose 3.13% premarket to $47.38 despite earnings miss, reflecting confidence in pipeline and mCOMBRIAX EU approval.
- Full-year 2026 guidance maintained at 10% revenue growth; Q2 projected $50M-$100M with balanced US-international split.
- CEO emphasized international partnerships as growth driver; litigation costs and R&D expenses remain key financial pressures.
Last Updated: 05/01/2026, 09:12 AM
Read Full TranscriptModerna investor slides for Q1/2026
Last Update: May 01, 2026
See full investor slides
Earnings
Latest Release
May 01, 2026
EPS / Forecast
-3.40 / -2.02
Revenue / Forecast
389M / 251.76M
Compare MRNA to Peers and Sector
Metrics to compare | MRNA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRNAPeersSector | |
|---|---|---|---|---|
P/E Ratio | - | −6.4x | −0.5x | |
PEG Ratio | - | 0.00 | 0.00 | |
Price / Book | - | 2.0x | 2.6x | |
Price / LTM Sales | - | 4.5x | 3.3x | |
Upside (Analyst Target) | −0.8% | 123.9% | 47.1% | |
Fair Value Upside | Unlock | −0.9% | 6.2% | Unlock |
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Moderna (MRNA) Stock Price Today?
The Moderna stock price today is 47.30 USD.
What Stock Exchange Does Moderna Trade On?
Moderna is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Moderna?
The stock symbol for Moderna is "MRNA."
What Is the Moderna Market Cap?
As of today, Moderna market cap is 18.59B USD.
What Is Moderna's Earnings Per Share (TTM)?
The Moderna EPS (TTM) is -7.25.
When Is the Next Moderna Earnings Date?
Moderna will release its next earnings report on Jul 30, 2026.
From a Technical Analysis Perspective, Is MRNA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Moderna Stock Split?
Moderna has split 0 times.
How Many Employees Does Moderna Have?
Moderna has 4700 employees.
What is the current trading status of Moderna (MRNA)?
As of May 05, 2026, Moderna (MRNA) is trading at a price of 47.30 USD, with a previous close of 45.37 USD. The stock has fluctuated within a day range of 45.29 USD to 47.97 USD, while its 52-week range spans from 22.28 USD to 59.55 USD.
What Is Moderna (MRNA) Price Target According to Analysts?
The average 12-month price target for Moderna is 42.89 USD, with a high estimate of 69 USD and a low estimate of 21 USD. 4 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an -9.31% Downside potential.
What Is the MRNA Premarket Price?
MRNA's last pre-market stock price is 45.25 USD. The pre-market share volume is 81,050.00, and the stock has decreased by -0.12, or -0.26%.
What Is the MRNA After Hours Price?
MRNA's last after hours stock price is 47.39 USD, the stock has decreased by 0.07, or 0.15%.
Industry Spotlight
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.